Skip to content

The Prevalence and Impacts of Nudix Hydrolase 15 (NUDT15) Gene Variants in Taiwanese Inflammatory Bowel Disease

The Prevalence and Impacts of Nudix Hydrolase 15 (NUDT15) Gene Variants in Taiwanese Inflammatory Bowel Disease

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06913998
Enrollment
65
Registered
2025-04-06
Start date
2023-12-27
Completion date
2026-11-30
Last updated
2025-04-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammatory Bowel Diseases, Neutropenia, Nudt15 Deficiency

Brief summary

The study will include participants who were diagnosed with inflammatory disease and followed up at National Taiwan University Children's Hospital. The investigators will check the NUDT15 gene test, if the participant agrees to do an additional blood test. The result of the gene test will be analyzed and compared with other clinical data.

Detailed description

In inflammatory bowel disease (IBD), thiopurines play an important role in maintenance of steroid-free remission but possess risk of life-threatening neutropenia, which is associated with gene variants of NUDT15 in Asians. In order to better incorporate thiopurines in clinical practice, the investigators aim to summarize the prevalence and impacts of NUDT15 variation in IBD in Taiwan. The study will include participants who were diagnosed with inflammatory disease and followed up at National Taiwan University Children's Hospital. The investigators will check the NUDT15 gene test, if the participant agrees to do an additional blood test. The result of the gene test will be analyzed and compared with other clinical data.

Interventions

None listed

Sponsors

National Taiwan University Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
1 Years to 25 Years
Healthy volunteers
No

Inclusion criteria

* Participants who are diagnosed with inflammatory bowel disease.

Exclusion criteria

* Participants who refused to have blood test for NUDT15 gene evaluation.

Design outcomes

Primary

MeasureTime frameDescription
Neutropenia2 yearsNeutropenia is defined as absolute neutrophil count \<1500/microL, and severe neutropenia is defined as absolute neutrophil count \<500/microL.

Countries

Taiwan

Contacts

Primary ContactWei-Ting Chen, MD
DBE98@tepch.gov.tw+886-2-2312-3456
Backup ContactJia-Feng Wu, MD, PhD
wjf@ntu.edu.tw+886-2-2312-3456

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026